Real world safety of ct-p10 (anti-cd 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases

HIGHLIGHTS

  • who: Wanruchada Katchamart from the This prospective study included patients who were diagnosed with rheumatic or autoimmune diseases at age of , years or older and received CT-, at Siriraj hospital and Ramathibodi hospital, Mahidol University, BangkokThailand between February , and May, . Written informed consent was obtained from all participants prior to enrollment. Demographic data, baseline characteristics, and clinical data related to CT-, infusion were collected at baseline and , months after infusions for occurrences of adverse reactions. Adverse events (AEs) were stratified into immediate and short-term AE. Immediate AE was defined as any reactions that occurred within , h . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?